Deals channel feed – Endpoints News

Deals channel feed

Evotec and Vifor launch joint kidney disease venture

6 years ago

Eli Lilly, Boehringer Ingelheim revise prolific diabetes pact, firing all cylinders for blockbuster Jardiance franchise

6 years ago

Andy Plump teams with MD Anderson on the race to cell therapy 2.0 — and they’re already planning a pivotal

6 years ago

Amgen takes a $2.7B stake in BeiGene, gaining a prominent ally in China to help seize a leading role in cancer drug commercialization and development

6 years ago

Astellas rejoins the autoimmune antibody craze with Pandion partnership

6 years ago

Roche signs up Dicerna in a $200M-plus cash alliance to help develop a hep B cocktail, capping the biotech's big year

6 years ago

Vivek Ramaswamy trades top execs and adds stealthy vant to $3B sale, while his new partner tosses Myovant $350M

6 years ago

Buoyed by blockbuster Vertex payments, the CF Foundation seeds new advances with $500M fund

6 years ago

Novartis' $111M bet on IL-17C drug turns sour — but MorphoSys, Galapagos will explore options

6 years ago

Roche — surprise — delays $4.3B Spark buyout again as regulators hover

6 years ago

Here’s a new way to raise money for your biotech. This trailblazer came out $61M ahead with a place on the NYSE

6 years ago

A deal-hungry Vertex ushers in three more gene editing programs as it closes out harbinger CRISPR deal

6 years ago

Novartis sends second wagon after KRAS gold rush

6 years ago

Zealand takes on Takeda's IBD drug with tiny buyout

6 years ago

Takeda tees up $420M deal for celiac antidote, continuing R&D refocus

6 years ago

That $335M JV Bayer set up on CRISPR/Cas9? They’re letting the biotech partner carry on

6 years ago

GSK offloads two vaccines in $1.1B deal as it works to revive the pipeline

6 years ago

Under new leadership, Novartis' Sandoz unit breaks up with digital therapeutics outfit Pear

6 years ago

Alexion pays $930M to buy out Achillion and its promising companion drug to Soliris

6 years ago

BridgeBio drops bid to reclaim Eidos after directors spurn 3 offers

6 years ago

AbbVie uncoupling costs Reata $330M in cold, hard cash

6 years ago

Neglected on Wall Street, little Stealth Bio finds an affluent chum with $30M in cash and high hopes for their PhIII drug

6 years ago

Parexel embraces real world evidence, enlisting Datavant to drill it into CRO workflow

6 years ago

UCB bags a rival to Soliris in $2.1B buyout deal — but will an increasingly vigilant FTC sign off?

6 years ago

First page Previous page 97 98 99100101 102 103 Next page Last page